Photo of Mark Garzotto, M.D.

Mark Garzotto M.D.

    • Associate Professor of Urology School of Medicine
    • Graduate Programs in Human Nutrition School of Medicine

Dr. Garzotto is a nationally recognized expert in the diagnosis and treatment of prostate cancer. He has published extensively on the development of risk-adapted models for use in clinical decision making when a PSA test is abnormally elevated. He specializes in the implementation of nerve-sparing techniques for the preservation of quality of life with special emphasis on maintaining erectile function. He has extensive expertise in the use of surgery for the treatment of aggressive prostate cancer. These include the use of combination therapy prior to prostate removal. He has published extensively and is widely known for his work on the treatment of locally advanced prostate cancer.     

  • Residency:

    • University of Florida, 1990-1995
  • Fellowship:

    • Urologic oncology, Memorial Sloan-Kettering Cancer Center, 1995-1999
  • Certifications:

    • American Board of Urology

Publications

  • "Effects of ω-3 Fatty Acids and Catechins on Fatty Acid Synthase in the Prostate : A Randomized Controlled Trial." Nutrition and Cancer  In: , Vol. 68, No. 8, 16.11.2016, p. 1309-1319.
  • "Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer : 10-year follow-up and immune correlates." Anti-Cancer Drugs In: , 23.09.2016.
  • "Relative sensitivities of DCE-MRI pharmacokinetic parameters to arterial input function (AIF) scaling." Journal of Magnetic Resonance In: , Vol. 269, 01.08.2016, p. 104-112.
  • "Gene-expression profiling of localized prostate cancer : Still miles to go before we sleep." Future Oncology In: , Vol. 12, No. 3, 01.02.2016, p. 273-276.
  • "Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention : Double-blind randomised study of pre-prostatectomy celecoxib or placebo." BJU International  In: , 2016.
  • "Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421 : A phase III metastatic castration resistant prostate cancer trial." International Journal of Cancer In: , Vol. 136, No. 8, 15.04.2015, p. 1856-1862.
  • "Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes." PLoS One In: , Vol. 9, No. 9, e104271, 08.09.2014.
  • "Circulating tumor cell counts are prognostic of overall survival in SWOG S0421 : A phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer." Journal of Clinical Oncology In: , Vol. 32, No. 11, 10.04.2014, p. 1136-1142.
  • "Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer." Clinical Cancer Research In: , Vol. 20, No. 5, 2014, p. 1306-1312.
  • "Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421) : A randomised phase 3 trial." The Lancet Oncology In: , Vol. 14, No. 9, 08.2013, p. 893-900.
  • "Agent Orange as a risk factor for high-grade prostate cancer." Cancer  In: , Vol. 119, No. 13, 01.07.2013, p. 2399-2404.
  • "Advances in the Multimodality Management of High-risk Prostate Cancer." Surgical Oncology Clinics of North America In: , Vol. 22, No. 2, 04.2013, p. 375-394.
  • "Feasibility of shutter-speed DCE-MRI for improved prostate cancer detection." Magnetic Resonance in Medicine In: , Vol. 69, No. 1, 01.2013, p. 171-178.
  • "Benign Prostatic Hyperplasia : A Brief Overview of Pathogenesis, Diagnosis, and Therapy." Techniques in Vascular and Interventional Radiology  In: , Vol. 15, No. 4, 12.2012, p. 261-264.
  • "Cell membrane water exchange effects in prostate DCE-MRI." Journal of Magnetic Resonance In: , Vol. 218, 05.2012, p. 77-85.
  • "Androgen deprivation therapy for prostate cancer : Not so simple." Asian Journal of Andrology  In: , Vol. 13, No. 2, 03.2011, p. 187-188.
  • "Minimal benefit of an endorectal balloon for prostate immobilization as verified by daily localization." Medical Dosimetry  In: , Vol. 36, No. 2, 2011, p. 195-199.
  • "Acupuncture for hot flashes in patients with prostate cancer." Urology  In: , Vol. 76, No. 5, 11.2010, p. 1182-1188.
  • "Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer." Cancer Research  In: , Vol. 70, No. 20, 15.10.2010, p. 7992-8002.
  • "Erythrocyte fatty acids and prostate cancer risk : A comparison of methods." Prostaglandins Leukotrienes and Essential Fatty Acids In: , Vol. 83, No. 3, 09.2010, p. 161-169.
  • "ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21 (Cancer Research (2010) 70, (3239-3248) DOI : 10.1158/0008-5472. CAN-09-3186)." Cancer Research In: , Vol. 70, No. 11, 01.06.2010, p. 4785.
  • "Contemporary management of high-risk localized prostate cancer." Current Urology Reports In: , Vol. 11, No. 3, 05.2010, p. 159-164.
  • "ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21." Cancer Research In: , Vol. 70, No. 8, 15.04.2010, p. 3239-3248.
  • "Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer." Cancer In: , Vol. 116, No. 7, 01.04.2010, p. 1699-1708.
  • "Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer." American Journal of Clinical Pathology In: , Vol. 133, No. 4, 04.2010, p. 654-661.
  • "CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity." Prostate In: , Vol. 70, No. 4, 01.03.2010, p. 433-442.
  • "Editorial Comment." Journal of Urology  In: , Vol. 183, No. 1, 01.2010, p. 123-124.
  • "Editorial comment." Journal of Urology  In: , Vol. 184, No. 2, 2010, p. 500.
  • "Folate intake and prostate cancer risk : A case-control study." Nutrition and Cancer  In: , Vol. 61, No. 5, 09.2009, p. 617-628.
  • "Lower urinary tract symptoms increase the risk of falls in older men." BJU International In: , Vol. 104, No. 1, 07.2009, p. 63-68.

Additional information

Edit profile